Evidence map›Paper›PMID 22705975›Full record

ArticleEpigenetics2012

Global DNA methylation levels in white blood cell DNA from sisters discordant for breast cancer from the New York site of the Breast Cancer Family Registry.

Lissette Delgado-Cruzata, Hui-Chen Wu, Mary Perrin, Yuyan Liao, Maya A Kappil, Jennifer S Ferris, Julie D Flom, Hulya Yazici, Regina M Santella, Mary Beth Terry

Abstract read
In one paragraph

Article in Epigenetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. DNA methylation as a promising landscape: A simple blood test for breast cancer prediction.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lissette Delgado-CruzataDepartment of Epidemiology, Mailman School of Public Health of Columbia University, New York, NY, USA.
Hui-Chen Wu
Mary Perrin
Yuyan Liao
Maya A Kappil
Jennifer S Ferris
Julie D Flom
Hulya Yazici
Regina M Santella
Mary Beth Terry

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
True Metal fac coreP30ES009089 · NIEHS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MATTHEW S PERZANOWSKI · 1998 to 2026
$44.7M
METROPOLITAN NEW YORK REGISTRY OF BREAST CANCER FAMILIESU01CA069398 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI TERRY, MARY BETH · 1995 to 2010
$10.5M
Epigentics and Female Reproductive CancersK07CA131094 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PERRIN, MARY COLETTE · 2008 to 2012
$801k
NCI NIH HHS CA-06-503NCI NIH HHS K07 CA131094NCI NIH HHS P30 CA013696NCI NIH HHS P30 CA13696NCI NIH HHS U01 CA069398NCI NIH HHS U01 CA69398NHGRI NIH HHS L30 HG004809NIEHS NIH HHS P30 ES009089
6 · The paper itself

Abstract

Lower global DNA methylation is associated with genomic instability and it is one of the epigenetic mechanisms relevant to carcinogenesis. Emerging evidence for several cancers suggests that lower overall levels of global DNA methylation in blood are associated with different cancer types, although less is known about breast cancer. We examined global DNA methylation levels using a sibling design in 273 sisters affected with breast cancer and 335 unaffected sisters from the New York site of the Breast Cancer Family Registry. We measured global DNA methylation in total white blood cell (WBC) and granulocyte DNA by two different methods, the [ ( 3) H]-methyl acceptance assay and the luminometric methylation assay (LUMA). Global methylation levels were only modestly correlated between sisters discordant for breast cancer (Spearman correlation coefficients ranged from -0.08 to 0.24 depending on assay and DNA source). Using conditional logistic regression models, women in the quartile with the lowest DNA methylation levels (as measured by the [ ( 3) H]-methyl acceptance assay) had a 1.8-fold (95% CI = 1.0-3.3) higher relative association with breast cancer than women in the quartile with the highest DNA methylation levels. When we examined the association on a continuous scale, we also observed a positive association (odds ratio, OR = 1.3, 95% CI = 1.0-1.7, for a one unit change in the natural logarithm of the DPM/μg of DNA). We observed no association between measures by the LUMA assay and breast cancer risk. If replicated in prospective studies, this study suggests that global DNA methylation levels measured in WBC may be a potential biomarker of breast cancer risk even within families at higher risk of cancer.

Indexed as

DNA MethylationAdultBreast NeoplasmsDNAFemaleHumansLeukocytesMiddle AgedNew YorkRegistriesSiblingsDNA

Identifiers

PMID22705975
PMCPMC3427282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.